Could Human HTA Committees be Replaced with AI Systems?
Our Blog
See below for an opinion on current matters around the world.
Land of the Long Wait Crowd: problems in New Zealand's medicine funding system
The Magic, Myths & Fantasy of ESG: What Does it Mean for Pharma?
From the sublime to the ridiculous: 5 years of Shawview Consulting blogs
Lessons learned: finance and resilience in post-COVID health systems
Jane Fonda, mix tapes & Australia's 5% discount rate: when time, health economics and ethics collide
It’s the economy, stupid: the economic benefits of health spending
Is 2022 the Pharma Industry’s ‘Call of Duty’ Moment?
More risk for government this time around in agreement negotiation
COVID-19 vaccination a 12-month success for science, governments and industry
Non-communicable diseases and the global countdown to 2030
The next 20-year PBS agenda: government commitments to new medicines spending
This could get messy: Trump’s New ‘Most Favoured Nation’ Executive Order on Medicine Pricing
What would Dr Who say?: Time travel and the macroeconomic impact of COVID-19
Global trends in cardiovascular deaths: 30 years of country data
Spanish Flu vs COVID-19: medical technology and health system resilience
Covid-19 - So how are we doing? Lessons from USA, UK and France and how to move forward
Creeping Through the Backdoor: Disruption in Medicine and Health
When resilience trumps efficiency in healthcare
'Coronavirus is yucky': a pandemic through the eyes of kids